D
Liquidia Corporation LQDA
$12.90 -$1.23-8.71%
Recommendation
Sell
Prev Close
$12.90
Volume
1,900,939
Avg Vol (90D)
880,407
Market Cap
$1.10B
Dividend & Yield
--
52-Week Range
$8.26 - $16.81
P/E (TTM)
--
EPS (TTM)
-$1.66
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
Liquidia (LQDA, $12.9) RSI Indicator left the oversold zone on April 04, 2025
4/5/2025 - Tickeron - Technical Analysis
Liquidia (LQDA, $12.9) price may climb as it broke lower Bollinger Band on Apr 04, 2025
4/5/2025 - Tickeron - Technical Analysis
Rangeley Capital LLC Takes Position in Liquidia Co. (NASDAQ:LQDA)
4/5/2025 - MarketBeat
Liquidia (LQDA, $14.52) Stochastic Oscillator left the oversold zone on April 02, 2025
4/3/2025 - Tickeron - Stocks
UPDATE -- Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
UPDATE -- Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
UPDATE Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - Globe Newswire
Liquidia Corp (LQDA) to Present at 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
Liquidia (LQDA, $14.75) entered Downtrend as Momentum indicator drops below 0 level on Mar 31, 2025
4/1/2025 - Tickeron - Stocks
Liquidia (LQDA, $14.75) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 31, 2025
4/1/2025 - Tickeron - Stocks
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - Globe Newswire
Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Consensus Target Price from Brokerages
4/1/2025 - Ticker Report
Liquidia says its request for Yutrepia final approval undergoes FDA review
3/28/2025 - Seeking Alpha - Healthcare
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA
3/28/2025 - TipRanks Financial Blog
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA
3/28/2025 - The Fly
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder
3/28/2025 - Globe Newswire
Liquidia (LQDA, $15.24) Stochastic Oscillator left the overbought zone on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 ...
3/27/2025 - GuruFocus
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
3/27/2025 - Globe Newswire
Liquidia Co. (NASDAQ:LQDA) Given Consensus Rating of "Buy" by Analysts
3/27/2025 - MarketBeat
Charles Schwab Investment Management Inc. Acquires 38,313 Shares of Liquidia Co. (NASDAQ:LQDA)
3/26/2025 - MarketBeat
Analysts Have Just Cut Their Liquidia Corporation (NASDAQ:LQDA) Revenue Estimates By 11%
3/24/2025 - Simply Wall St
Q2 Earnings Forecast for Liquidia Issued By Lifesci Capital
3/24/2025 - MarketBeat
HC Wainwright Predicts Liquidia's Q1 Earnings (NASDAQ:LQDA)
3/24/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$14.00M
EBITDA (TTM)
-$119.70M
EBIT (TTM)
-$121.29M
Net Income (TTM)
-$130.39M
Balance Sheet
Total Assets (Q)
$230.31M
Total Debt (Q)
$122.39M
Total Liabilities (Q)
$153.04M
Book Value Per Share (Q)
$0.9125
Cash Flow
Cash from Operations (TTM)
-$93.42M
Cash from Investing (TTM)
-$8.44M
Cash from Financing (TTM)
$194.66M
Net Change in Cash (TTM)
$92.80M
Filings
Filing Date
Wednesday, March 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.17
7-Day Total Return
-15.35%
30-Day Total Return
-18.82%
60-Day Total Return
3.53%
90-Day Total Return
21.13%
Year to Date Total Return
6.61%
1-Year Total Return
-17.89%
2-Year Total Return
91.68%
3-Year Total Return
78.92%
5-Year Total Return
130.36%
52-week Low
Aug 19, 2024 - $8.26
52-week High
Feb 20, 2025 - $16.81
Valuation
Market Cap
$1.10B - Small Cap
Enterprise Value
$1.05B
Price/Sales (TTM)
78.04
Price/Book (Q)
14.14
Dividends and Shares
Shares Outstanding
84.67M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.liquidia.com
Phone Number
919 328 4400
Address
419 Davis Drive
Morrisville, NC 27560
Country
United States
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include... more
NASDAQ 04/04/2025 4:00PM Eastern Quotes delayed
Weiss Ratings